#1 Clinical Trials Search in Europe

Kyv-101

KYV-101, a fully-human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is currently being studied in clinical trials for various autoimmune diseases. These trials aim to assess the safety, tolerability, and clinical effectiveness of KYV-101 in treating conditions such as idiopathic inflammatory myopathies, diffuse cutaneous systemic sclerosis, systemic lupus erythematosus with nephritis, and ANCA-associated vasculitis. The studies involve administering a single dose of KYV-101 to participants and monitoring their progress over an extended period.

Table of Contents

What is KYV-101?

KYV-101 is an innovative medical treatment known as a CAR T-cell therapy. Specifically, it is described as an autologous fully-human anti-CD19 CAR T-cell immunotherapy[1]. Let’s break down what this means:

  • Autologous: This means the therapy uses the patient’s own cells, which are modified and then given back to the patient.
  • Fully-human: The components used to modify the cells are derived from human sources, which may help reduce the risk of immune reactions.
  • Anti-CD19: The modified cells are designed to target a specific protein called CD19, which is found on certain types of immune cells.
  • CAR T-cell: CAR stands for Chimeric Antigen Receptor. This is a special protein added to T-cells (a type of immune cell) that helps them recognize and attack specific targets in the body.

How KYV-101 Works

KYV-101 works by modifying a patient’s own T-cells to target and eliminate cells that express CD19, a protein found on B-cells. B-cells are a type of immune cell that can sometimes malfunction and contribute to autoimmune diseases[1][2].

The process involves:

  1. Collecting T-cells from the patient’s blood
  2. Modifying these T-cells in a laboratory to express the anti-CD19 CAR
  3. Multiplying these modified cells
  4. Infusing the CAR T-cells back into the patient

Once in the body, these modified T-cells can recognize and attack B-cells, potentially reducing the autoimmune response that causes disease symptoms.

Conditions Treated with KYV-101

KYV-101 is being studied for the treatment of several B cell-driven autoimmune diseases[1]. These include:

  • Idiopathic Inflammatory Myopathies (IIM): A group of conditions that cause muscle inflammation, including:
    • Dermatomyositis (DM)
    • Necrotizing myopathy
    • Anti-HMGCoA-associated myopathy
    • Polymyositis (PM)
  • Diffuse Cutaneous Systemic Sclerosis (dcSSc): A condition that causes hardening and tightening of the skin and internal organs
  • Systemic Lupus Erythematosus (SLE) with nephritis: An autoimmune disease that can affect various parts of the body, particularly the kidneys in this case
  • ANCA-Associated Vasculitis (AAV): A group of diseases that cause inflammation of blood vessels

How KYV-101 is Administered

KYV-101 is administered as a single intravenous (IV) infusion. The dosage used in current clinical trials is 1×10^8 CAR+ T cells[1][2].

Before receiving KYV-101, patients undergo a process called lymphodepletion. This involves receiving chemotherapy drugs to reduce the number of existing immune cells in the body. The drugs used are:

  • Cyclophosphamide: 300 mg/m2
  • Fludarabine: 30 mg/m2

These drugs are given intravenously daily for 3 days, typically 5 to 7 days before the KYV-101 infusion[1].

Current Clinical Trials

There are currently two clinical trials studying KYV-101:

  1. CARTIMMUNE Study (NCT06152172): This trial is studying KYV-101 in patients with various autoimmune diseases, including IIM, dcSSc, SLE with nephritis, and AAV. It aims to enroll up to 24 participants who will receive a single dose of KYV-101 and be followed for 2 years[1].
  2. ANCA Vasculitis Study (NCT06590545): This is a Phase I/II trial specifically focusing on patients with ANCA-IgG-positive AAV. The study aims to assess the safety and efficacy of KYV-101 in these patients, with a follow-up time of 52 weeks[2].

Safety and Efficacy

The primary focus of the current clinical trials is to assess the safety and efficacy of KYV-101. Key aspects being monitored include:

  • Incidence and severity of adverse events (AEs)
  • Occurrence of cytokine release syndrome (CRS) or immune cell-associated neurotoxicity syndrome (ICANS)
  • Clinical efficacy in treating the targeted autoimmune conditions
  • ANCA seroconversion rate (for the ANCA vasculitis trial)

It’s important to note that as KYV-101 is still in clinical trials, its full safety profile and efficacy are not yet established[1][2].

Potential Benefits of KYV-101

While the full benefits of KYV-101 are still being studied, researchers hope this therapy could offer several advantages for patients with autoimmune diseases:

  • Potential for long-term remission or even cure of the autoimmune condition
  • Possibility of reducing or eliminating the need for ongoing immunosuppressive medications
  • Targeted approach that specifically addresses B-cell driven autoimmune processes
  • Single infusion treatment, which could be more convenient than ongoing therapies

However, it’s crucial to remember that these potential benefits are still being investigated in clinical trials, and more research is needed to confirm the long-term effects and efficacy of KYV-101[1][2].

Aspect Details
Drug Name KYV-101
Type of Therapy Fully-human anti-CD19 CAR T-cell therapy
Conditions Studied Idiopathic inflammatory myopathies, Diffuse cutaneous systemic sclerosis, Systemic lupus erythematosus with nephritis, ANCA-associated vasculitis
Administration Single intravenous infusion of 1×10^8 CAR+ T cells
Pre-treatment Lymphodepleting chemotherapy with cyclophosphamide and fludarabine
Primary Outcomes Safety (incidence and severity of adverse events), ANCA seroconversion rate, clinical efficacy
Follow-up Duration Up to 2 years
Key Secondary Outcomes Changes in immunoglobulin levels, B-cell and T-cell numbers, disease activity scores, time to relapse, duration of remission

FAQ

  • What is KYV-101? KYV-101 is a fully-human anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. It's a type of immunotherapy that uses modified T-cells to target specific cells in the body, in this case, B-cells that express CD19.
  • What conditions are being studied with KYV-101? KYV-101 is being studied for various autoimmune diseases, including idiopathic inflammatory myopathies, diffuse cutaneous systemic sclerosis, systemic lupus erythematosus with nephritis, and ANCA-associated vasculitis.
  • How is KYV-101 administered? KYV-101 is administered as a single intravenous (IV) infusion. The dosage used in the trials is 1×10^8 CAR+ T cells.
  • What is the purpose of the lymphodepleting chemotherapy before KYV-101 administration? Lymphodepleting chemotherapy, using cyclophosphamide and fludarabine, is administered 5 to 7 days before KYV-101. This helps prepare the body to receive the CAR T-cells by reducing the number of existing immune cells.
  • How long do the clinical trials follow the participants? The clinical trials follow participants for different durations. One study follows participants for 2 years, while another has a follow-up period of 52 weeks (1 year).

Ongoing Clinical Trials on Kyv-101

  • A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study Comparing Rituximab and KYV-101 for Patients with Active, ACPA-Positive, Treatment-Resistant Rheumatoid Arthritis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of KYV-101 Therapy for Patients with Refractory Generalized Myasthenia Gravis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of KYV-101, Fludarabine Phosphate, and Cyclophosphamide Monohydrate for Patients with Treatment-Resistant ANCA Vasculitis

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany Italy

Glossary

  • Chimeric Antigen Receptor (CAR) T-cell therapy: A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells or, in this case, specific cells involved in autoimmune diseases.
  • Autoimmune disease: A condition in which your immune system mistakenly attacks your body. The immune system normally guards against germs like bacteria and viruses, but in autoimmune diseases, it attacks your body's own tissues.
  • ANCA-associated vasculitis (AAV): A group of diseases characterized by inflammation of blood vessels, associated with the presence of antineutrophil cytoplasmic antibodies (ANCA) in the blood.
  • Systemic lupus erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • Diffuse cutaneous systemic sclerosis (dcSSc): A subtype of systemic sclerosis, characterized by widespread skin thickening and potential internal organ involvement.
  • Idiopathic inflammatory myopathies (IIM): A group of disorders characterized by inflammation of muscles, which can include conditions like dermatomyositis and polymyositis.
  • Lymphodepleting chemotherapy: A treatment that reduces the number of lymphocytes (a type of white blood cell) in the body, often used before CAR T-cell therapy to improve its effectiveness.
  • Cytokine release syndrome (CRS): A condition that can occur after some types of immunotherapy, including CAR T-cell therapy, characterized by fever, low blood pressure, and respiratory problems.
  • Immune cell-associated neurotoxicity syndrome (ICANS): A neurological side effect that can occur after CAR T-cell therapy, potentially causing confusion, difficulty speaking, or seizures.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent. In the context of these trials, it refers to the change from positive to negative ANCA status.

References